[6] In 2012, Horizon Capital and FMO invested in Biopharma for building a new biopharmaceutical production factory equipped with a quality control laboratory.

[10] On this occasion, the company handed over medicines worth ₴1 million, for the needs of the Ministry of Defense and the treatment of military personnel.

At the new facilities, the company will produce Albumin, Bioven, and Immunoglobulin that help treat diseases caused by immunodeficiency.

[14][15][16][17] The opening of the new complex took place in summer 2018 Vasyl Khmelnytsky and his partners invested $42 million in the research and production facility.

[19] This technology enables to extract lifesaving drugs, requires advanced research and development, GMP-certified equipment and facilities.

[22] This decision was made in view of the fact that STADA will be able to bring investment and new expertise in the production and promotion of medicines.

Biopharma's shareholders maintained the production of donor plasma drugs and focused on its development both in Ukraine and abroad.

In 2017, as part of a public-private partnership, Biopharma invested over $3.5 million in the reconstruction and modernization of the Sumy Regional Blood Service Center.

[33] As a result, a Memorandum of Cooperation was concluded and signed, which makes it possible to implement a system of public control over the production of the drug for patients with hemophilia "BioClot A".

[41][42][43][44][45][46] In September 2020 Biopharma has completed clinical trials of immunoglobulin (Bioven) in the complex therapy of patients with pneumonia caused by coronavirus infection COVID-19.